open access
Pre-hospital treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams. Expert position update 2022
Affiliations- Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
- Department of Emergency Medicine Medical University of Bialystok, Poland
- Department of Cardiology, Pomeranian Medical University, Szczecin, Poland
- Institute of Clinical Sciences, Medical University of Maria Skłodowska-Curie, Warsaw, Poland
- Gajda-Med Medical Center, Pultusk, Poland
- 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
- Department of Cardiology, Medical University of Silesia, Katowice, Poland
- Mossakowski Medical Research Institute, Polish Academy of Science, Warsaw, Poland
- Independent Laboratory of Invasive Cardiology, Pomeranian Medical University, Szczecin, Poland
- 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
- Department of Cardiology and Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland
- 1st Department of Cardiology, Medical University of Gdansk, Poland
- Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, Nicolaus Copernicus University, Torun, Poland
- Department of Congenital Heart Defects, National Institute of Cardiology, Warsaw, Poland
- Institute of Medical Sciences, Collegium Medicum, Jan Kochanowski University, Kielce, Poland
- Department of Internal Medicine and Geriatric Cardiology, Centre of Postgraduate Medical Education, Warsaw, Poland
- Department of Epidemiology and Health Promotion, School of Public Health, Centre of Postgraduate Medical Education, Warsaw, Poland
- 2nd Chair and Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
- 1st Department of Cardiology, Medical University of Lodz, Bieganski Hospital, Łodz, Poland
- University of Information Technology and Management in Rzeszow, Poland
- The National Institute of Cardiology, Department of Cardiology, Bielanski Hospital, Warsaw, Poland
- Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland
- Department of Interventional Cardiology, Institute of Cardiology, Jagiellonian University Medical College, John Paul II Hospital in Krakow, Poland
- Faculty of Medicine, University of Technology in Katowice, Poland
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Poland
- Department of Cardiology, Medical University of Vienna, Austria
- Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland
- Research Unit, Maria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland
- Department of Emergency Medicine and Disaster Medicine, Medical University of Lodz, Lodz, Poland
- Department of Interventional Cardiology and Angiology, National Institute of Cardiology, Warsaw, Poland
- Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
- Department of Cardiology, Medical Uniwersity of Lublin, Lublin, Poland
- Department of Invasive Cardiology, Medical University of Lodz, Poland
open access
Abstract
Abstract
About this articleTitle
Pre-hospital treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams. Expert position update 2022
Journal
Issue
Article type
Review article
Pages
94-104
Published online
2022-03-31
Page views
9583
Article views/downloads
713
DOI
10.5603/MRJ.2022.0013
Bibliographic record
Medical Research Journal 2022;7(1):94-104.
Authors
Jacek Kubica
Piotr Adamski
Jerzy R. Ładny
Jarosław Kaźmierczak
Tomasz Fabiszak
Krzysztof Filipiak
Robert Gajda
Mariusz Gąsior
Zbigniew Gąsior
Robert Gil
Jarosław Gorący
Stefan Grajek
Leszek Gromadziński
Marcin Gruchała
Grzegorz Grześk
Piotr Hoffman
Miłosz J. Jaguszewski
Marianna Janion
Piotr Jankowski
Zbigniew Kalarus
Jarosław D. Kasprzak
Andrzej Kleinrok
Wacław Kochman
Aldona Kubica
Wiktor Kuliczkowski
Jacek Legutko
Maciej Lesiak
Klaudiusz Nadolny
Eliano P. Navarese
Piotr Niezgoda
Małgorzata Ostrowska
Przemysław Paciorek
Jolanta Siller-Matula
Łukasz Szarpak
Dariusz Timler
Adam Witkowski
Wojciech Wojakowski
Andrzej Wysokiński
Marzenna Zielińska
References (78)- Kubica J, Adamski P, Paciorek P, et al. Anti-aggregation therapy in patients with acute coronary syndrome - recommendations for medical emergency teams. Experts' standpoint. Kardiol Pol. 2017; 75(4): 399–408.
- Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 7(39): 119–177.
- Valgimigli M, Bueno H, Byrne RA, et al. ESC Scientific Document Group, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018; 39(3): 213–260.
- Kubica J, Adamski P, Paciorek P, et al. Treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams: Focus on antiplatelet therapies. Updated experts' standpoint. Cardiol J. 2018; 25(3): 291–300.
- Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021; 42(14): 1289–1367.
- Borowicz A, Nadolny K, Bujak K, et al. Paramedic versus physician-staffed ambulances and prehospital delays in the management of patients with ST-segment elevation myocardial infarction. Cardiol J. 2021; 28(1): 110–117.
- Lopes RD, Siha H, Fu Y, et al. Diagnosing acute myocardial infarction in patients with left bundle branch block. Am J Cardiol. 2011; 108(6): 782–788.
- Chan AW, Kornder J, Elliott H, et al. Improved survival associated with pre-hospital triage strategy in a large regional ST-segment elevation myocardial infarction program. JACC Cardiovasc Interv. 2012; 5(12): 1239–1246.
- Widimsky P, Rohác F, Stásek J, et al. Primary angioplasty in acute myocardial infarction with right bundle branch block: should new onset right bundle branch block be added to future guidelines as an indication for reperfusion therapy? Eur Heart J. 2012; 33(1): 86–95.
- Dhruva VN, Abdelhadi SI, Anis A, et al. ST-Segment Analysis Using Wireless Technology in Acute Myocardial Infarction (STAT-MI) trial. J Am Coll Cardiol. 2007; 50(6): 509–513.
- Bagai A, Jollis JG, Dauerman HL, et al. Emergency department bypass for ST-Segment-elevation myocardial infarction patients identified with a prehospital electrocardiogram: a report from the American Heart Association Mission: Lifeline program. Circulation. 2013; 128(4): 352–359.
- Welsh RC, Chang W, Goldstein P, et al. Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trial. Heart. 2005; 91(11): 1400–1406.
- Steg PhG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33(20): 2569–2619.
- Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37(3): 267–315.
- ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. The Lancet. 1995; 345(8951): 669–685.
- Parodi G. Editor's Choice-Chest pain relief in patients with acute myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2016; 5(3): 277–281.
- Kubica J, Kubica A, Jilma B, et al. Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. Int J Cardiol. 2016; 215: 201–208.
- Ostrowska M, Gorog D. Does morphine remain a standard of care in acute myocardial infarction? Medical Research Journal. 2020; 5(1): 46–49.
- Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016; 37(3): 245–252.
- Hobl EL, Stimpfl T, Ebner J, et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2014; 63(7): 630–635.
- Parodi G, Bellandi B, Xanthopoulou I, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv. 2014; 8(1): e001593.
- de Waha S, Eitel I, Desch S, et al. Intravenous morphine administration and reperfusion success in ST-elevation myocardial infarction: insights from cardiac magnetic resonance imaging. Clin Res Cardiol. 2015; 104(9): 727–734.
- Meine TJ, Roe MT, Chen AY, et al. CRUSADE Investigators. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J. 2005; 149(6): 1043–1049.
- Puymirat E, Lamhaut L, Bonnet N, et al. Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) programme. Eur Heart J. 2016; 37(13): 1063–1071.
- Meine TJ, Roe MT, Chen AY, et al. CRUSADE Investigators. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J. 2005; 149(6): 1043–1049.
- Iakobishvili Z, Porter A, Battler A, et al. Effect of narcotic treatment on outcomes of acute coronary syndromes. Am J Cardiol. 2010; 105(7): 912–916.
- Gue YX, Spinthakis N, Farag M, et al. Impact of Preadmission Morphine on Reinfarction in Patients With ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention: A Meta-Analysis. Clin Pharmacol Ther. 2020; 108(1): 54–62.
- Batchelor R, Liu DH, Bloom J, et al. Association of periprocedural intravenous morphine use on clinical outcomes in ST-elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention: Systematic review and meta-analysis. Catheter Cardiovasc Interv. 2020; 96(1): 76–88.
- Ibrahim K, Shah R, Goli RR, et al. Fentanyl Delays the Platelet Inhibition Effects of Oral Ticagrelor: Full Report of the PACIFY Randomized Clinical Trial. Thromb Haemost. 2018; 118(8): 1409–1418.
- Senguttuvan NB, Suman F, Paneerselvam T, et al. Comparison of the effect of Morphine and Fentanyl in patients with acute coronary syndrome receiving Ticagrelor - The COMET (Comparison Morphine, Fentayl and Ticagrelor) randomized controlled trial. Int J Cardiol. 2021; 330: 1–6.
- Tavenier AH, Hermanides RS, Ottervanger JP, et al. Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial. Eur Heart J Cardiovasc Pharmacother. 2022; 8(1): 4–12.
- Alexopoulos D, Barampoutis N, Gkizas V, et al. Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study. Clin Pharmacokinet. 2016; 55(3): 359–367.
- Parodi G, Xanthopoulou I, Bellandi B, et al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. J Am Coll Cardiol. 2015; 65(5): 511–512.
- Rollini F, Franchi F, Angiolillo DJ, et al. Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study. J Am Coll Cardiol. 2016; 67(17): 1994–2004.
- Niezgoda P, Sikora J, Barańska M, et al. Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. Thromb Haemost. 2017; 117(4): 718–726.
- Sikora J, Niezgoda P, Barańska M, et al. METoclopramide Administration as a Strategy to Overcome MORPHine-ticagrelOr Interaction in PatientS with Unstable Angina PectorIS-The METAMORPHOSIS Trial. Thromb Haemost. 2018; 118(12): 2126–2133.
- Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019; 40(2): 87–165.
- Adamski P, Adamska U, Ostrowska M, et al. New directions for pharmacotherapy in the treatment of acute coronary syndrome. Expert Opin Pharmacother. 2016; 17(17): 2291–2306.
- Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11): 1045–1057.
- Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013; 127(5): 634–640.
- Sørensen R, Hansen M, Abildstrom S, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. The Lancet. 2009; 374(9706): 1967–1974.
- Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010; 170(16): 1433–1441.
- Oldgren J, Budaj A, Granger CB, et al. RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011; 32(22): 2781–2789.
- Tantry U, Chaudhary R, Kubica J, et al. Cangrelor for the treatment of patients with Arterial Thrombosis. Expert Opin Pharmacother. 2018; 19(12): 1389–1398.
- Kubica J, Kozinski M, Navarese EP, et al. Cangrelor: an emerging therapeutic option for patients with coronary artery disease. Curr Med Res Opin. 2014; 30(5): 813–828.
- Umińska JM, Ratajczak J, Buszko K, et al. Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. Cardiol J. 2020; 27(6): 780–788.
- Ratajczak J, Łach P, Umińska JM, et al. Mild therapeutic hypothermia after out-of-hospital cardiac arrest: What does really matter? Cardiol J. 2021; 28(2): 293–301.
- Tomala MT, Trąbka-Zawicki A, Machnik A, et al. Ticagrelor effectively inhibits platelet aggregation in comatose survivors of cardiac arrest undergoing primary percutaneous coronary intervention treated with mild therapeutic hypothermia. Cardiol J. 2021 [Epub ahead of print].
- O'Donoghue M, Boden WE, Braunwald E, et al. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2008; 300(1): 71–80.
- Mehta SR, Cannon CP, Fox KAA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA. 2005; 293(23): 2908–2917.
- Fox KAA, Clayton TC, Damman P, et al. FIR Collaboration. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol. 2010; 55(22): 2435–2445.
- Fanning JP, Nyong J, Scott IA, et al. Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era. Cochrane Database Syst Rev. 2016(5): CD004815.
- Elgendy IY, Mahmoud AN, Wen X, et al. Meta-Analysis of Randomized Trials of Long-Term All-Cause Mortality in Patients With Non-ST-Elevation Acute Coronary Syndrome Managed With Routine Invasive Versus Selective Invasive Strategies. Am J Cardiol. 2017; 119(4): 560–564.
- Schüpke S, Neumann FJ, Menichelli M, et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2019; 381(16): 1524–1534.
- Kubica J, Jaguszewski M. ISAR-REACT 5 - What have we learned? Cardiol J. 2019; 26(5): 427–428.
- Angoulvant D, Sabouret P, Savage MP. NSTE-ACS ESC Guidelines Recommend Prasugrel as the Preferred P2Y12 Inhibitor: A Contrarian View. Am J Cardiovasc Drugs. 2021; 21(5): 483–486.
- Crea F, Thiele H, Sibbing D, et al. Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy. Eur Heart J. 2021; 42(31): 2973–2985.
- Arslan F, Damman P, Zwart B, et al. 2020 ESC Guidelines on acute coronary syndrome without ST-segment elevation : Recommendations and critical appraisal from the Dutch ACS and Interventional Cardiology working groups. Neth Heart J. 2021; 29(11): 557–565.
- Kubica J, Jaguszewski M, Ostrowska M, et al. Creative scientific dispute — different points of view on the protocol and execution of the ISAR-REACT 5 trial. Medical Research Journal. 2020; 5(1): 41–45.
- Navarese EP, Khan SU, Kołodziejczak M, et al. Comparative Efficacy and Safety of Oral P2Y Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials. Circulation. 2020; 142(2): 150–160.
- Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013; 369(11): 999–1010.
- Dworeck C, Redfors B, Angerås O, et al. Association of Pretreatment With P2Y12 Receptor Antagonists Preceding Percutaneous Coronary Intervention in Non-ST-Segment Elevation Acute Coronary Syndromes With Outcomes. JAMA Netw Open. 2020; 3(10): e2018735.
- Tarantini G, Mojoli M, Varbella F, et al. Timing of Oral P2Y Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. J Am Coll Cardiol. 2020; 76(21): 2450–2459.
- Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009; 120(25): 2577–2585.
- Buszko K, Kubica K, Hobl EL, et al. Pharmacokinetic Modeling of Morphine's Effect on Plasma Concentrations of Ticagrelor and Its Metabolite in Healthy Volunteers. Front Physiol. 2021; 12: 663170.
- Hobl EL, Reiter B, Schoergenhofer C, et al. Morphine decreases ticagrelor concentrations but not its antiplatelet effects: a randomized trial in healthy volunteers. Eur J Clin Invest. 2016; 46(1): 7–14.
- Hobl EL, Reiter B, Schoergenhofer C, et al. Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers. Clin Res Cardiol. 2016; 105(4): 349–355.
- Schoergenhofer C, Hobl EL, Staudinger T, et al. Prasugrel in critically ill patients. Thromb Haemost. 2017; 117(8): 1582–1587.
- Adamski P, Sikora J, Laskowska E, et al. Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. PLoS One. 2017; 12(10): e0186013.
- Adamski P, Adamska U, Ostrowska M, et al. Evaluating current and emerging antithrombotic therapy currently available for the treatment of acute coronary syndrome in geriatric populations. Expert Opin Pharmacother. 2018; 19(13): 1415–1425.
- Ostrowska M, Kubica J, Adamski P, et al. Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing. Front Cardiovasc Med. 2019; 6: 176.
- Kubica J, Adamski P, Gorog DA, et al. Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. Cardiol J. 2021 [Epub ahead of print].
- Kubica J, Adamski P, Niezgoda P, et al. A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study. Cardiol J. 2021; 28(4): 607–614.
- Tubek S, Kuliczkowski W, Gąsior M, et al. Antiplatelets in acute coronary syndrome in Poland - from guidelines to clinical practice. Postepy Kardiol Interwencyjnej. 2021; 17(2): 141–154.
- Knuuti J, Wijns W, Saraste A, et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41(3): 407–477.
- Kubica J, Adamski P, Niezgoda P, et al. Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. Cardiol J. 2020; 27(6): 661–676.
- Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011; 57(6): 672–684.
- Directive of the Minister of Health dated 20 April 2016 on medical rescue procedures and health services different than medical rescue procedures, which can be performed by paramedic.